Please use this identifier to cite or link to this item: http://hdl.handle.net/10662/19325
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDurán Gómez, Noelia-
dc.contributor.authorLópez Jurado, Casimiro Fermín-
dc.contributor.authorNadal Delgado, Marta-
dc.contributor.authorPérez Civantos, Demetrio Víctor-
dc.contributor.authorGuerrero Martín, Jorge-
dc.contributor.authorCáceres León, Macarena Celina-
dc.date.accessioned2024-01-25T12:45:59Z-
dc.date.available2024-01-25T12:45:59Z-
dc.date.issued2022-
dc.identifier.urihttp://hdl.handle.net/10662/19325-
dc.description.abstractBackground: Chemotherapy-related cognitive impairment (CRCI), or “chemobrain,” isdefined as a phenomenon of cognitive deficits in cancer patients after chemotherapy and is characterized by deficits in areas of cognition, including memory, attention, speed of processing, and executive function, which seriously affect quality of life. The purpose of this study is to investigate the impact of CRCI in breast cancer (BC) patients in chemotherapy treatment (CT+) or not (CT−) and to analyze their relationship with detectable objective changes in cerebral activity during the execution of a phonological and semantic verbal fluency task (PVF and SVF). Methods: An observational, cross-sectional study was carried out at Badajoz University Hospital (Spain). A total of 180 women with BC were included. We used Cognitive Scale (FACT-Cog) for neuropsychological subjective assessment, obtaining scores of perceived cognitive impairment (PCI), and near-infrared spectroscopy system (NIRS) for neuropsychological objective assessment during a verbal fluency task (PVF and SVF), determining alterations in the prefrontal cortex (PFC) assessed as changes in regional saturation index (rSO2). Results: A total of 41.7% percent of the patients in the sample had PCI. CT+ was significantly associated with a worse impact in PCI (X¯ = 50.60 ± 15.64 vs. X¯ = 55.01 ± 12.10; p = 0.005). Average rSO2 decreased significantly in CT+ (X¯ = 63.30 ± 8.02 vs. X¯ = 67.98 ± 7.80; p < 0.001), and BC patients showed a significant decrease in PVF and SVF on average (X¯ = 41.99 ± 9.52 vs. X¯ = 47.03 ± 9.31, and X¯ = 33.43 ± 11.0 vs. X¯ = 36.14 ± 10.68, respectively; p < 0.001). Conclusions: Our findings suggest that cognitive impairments in the domain of executive functioning exist among patients with BC who received CT. The results corroborate the hypothesis that CT is an important factor in cognitive impairment in patients with BC, which has been demonstrated by both subjective (PCI) and objective (PVF, SVF, and rSO2) neuropsychological measures. The combination of doxorubicin, cyclophosphamide, and docetaxel induce cognitive impairment.es_ES
dc.description.sponsorshipSupported by grant no. IB18101 (Support to the Action Plans of Registered Research Groups). Consejería de Economía e Infraestructuras. Junta de Extremadura (Spain), and the European Regional Development Fund.es_ES
dc.format.extent18 p.es_ES
dc.format.mimetypeapplication/pdfen_US
dc.language.isoenges_ES
dc.publisherMDPI-
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectCognitive impairmentes_ES
dc.subjectCerebral blood flowes_ES
dc.subjectNear-infrared spectroscopyes_ES
dc.subjectCáncer de mamaes_ES
dc.subjectCorteza prefrontales_ES
dc.subjectDeterioro cognitivoes_ES
dc.subjectBreast neoplasmes_ES
dc.subjectNeoplasia de mamaes_ES
dc.subjectDorsolateral prefrontal cortexes_ES
dc.subjectCorteza prefrontal dorsolaterales_ES
dc.titleChemotherapy-related cognitive impairment in patients with breast cancer based on functional assessment and NIRS analysises_ES
dc.typearticlees_ES
dc.description.versionpeerReviewedes_ES
europeana.typeTEXTen_US
dc.rights.accessRightsopenAccesses_ES
dc.subject.unesco3201.01 Oncologíaes_ES
europeana.dataProviderUniversidad de Extremadura. Españaes_ES
dc.identifier.bibliographicCitationDurán-Gómez N, López-Jurado CF, Nadal-Delgado M, Pérez-Civantos D, Guerrero-Martín J, Cáceres MC. Chemotherapy-Related Cognitive Impairment in Patients with Breast Cancer Based on Functional Assessment and NIRS Analysis. J Clin Med. 2022 Apr 23;11(9):2363. doi: 10.3390/jcm11092363.es_ES
dc.type.versionpublishedVersiones_ES
dc.contributor.affiliationUniversidad de Extremadura. Departamento de Enfermeríaes_ES
dc.contributor.affiliationHospital Universitario de Badajoz-
dc.relation.publisherversionhttps://www.mdpi.com/2077-0383/11/9/2363es_ES
dc.identifier.doi10.3390/jcm11092363-
dc.identifier.publicationtitleJournal of Clinical Medicinees_ES
dc.identifier.publicationissue9es_ES
dc.identifier.publicationfirstpage2363-1es_ES
dc.identifier.publicationlastpage2363-18-
dc.identifier.publicationvolume11es_ES
dc.identifier.e-issn2077-0383-
dc.identifier.orcid0000-0003-1001-7538es_ES
dc.identifier.orcid0000-0002-6541-8358es_ES
dc.identifier.orcid0000-0003-4115-9790es_ES
dc.identifier.orcid0000-0003-4828-5028es_ES
dc.identifier.orcid0000-0001-7932-4400es_ES
dc.identifier.orcid0000-0002-0942-6345es_ES
Appears in Collections:DENFE - Artículos

Files in This Item:
File Description SizeFormat 
jcm11092363.pdf1,73 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons